BD (NYSE:BDX) today announced the introduction of the Elyra thulium fiber laser (TFL) system for treating kidney stones.

In early May 2026, Becton, Dickinson and Company reported higher quarterly sales of US$4.71 billion but swung to a net loss, raised its full-year adjusted earnings guidance, completed the divestiture ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the launch of the Elyra Thulium Fiber Laser (TFL ...

The scientific-instrument company Waters will deepen its biological sciences footprint by merging with the biosciences and diagnostic solution business of Becton, Dickinson (BD). The companies value ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.

CHEONGJU, South Korea--(BUSINESS WIRE)--Celltrion Pharm (KOSDAQ: 068706), a South Korean biopharmaceutical firm, said on September 16 that it has inked a strategic trilateral agreement with a ...

BD has settled on a new name for its new company, the independent spinout that will house its billion-dollar diabetes care business. Embecta is set to launch as its own, publicly traded brand in the ...

Dubai, United Arab Emirates – The Dubai branch of BD (Becton, Dickinson, and Company) (NYSE: BDX), a leading global medical technology company, is marking its presence at the region’s key healthcare ...